financetom
Business
financetom
/
Business
/
UnitedHealth Narrows Full-Year Earnings Outlook Range Despite Third-Quarter Beat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UnitedHealth Narrows Full-Year Earnings Outlook Range Despite Third-Quarter Beat
Oct 17, 2024 12:44 PM

09:09 AM EDT, 10/15/2024 (MT Newswires) -- UnitedHealth Group ( UNH ) narrowed its full-year earnings outlook on Tuesday amid a higher-than-expected impact from business disruptions tied to a cybersecurity incident earlier in the year, while the health insurer reported third-quarter results above market estimates.

Adjusted earnings are now set to come in between $27.50 and $27.75 per share for 2024, reflecting a lower top end from the company's previous guidance of $28. The consensus on Capital IQ is for normalized EPS of $27.69. UnitedHealth's ( UNH ) stock declined 3.5% in premarket activity.

The guidance assumes an estimated per-share hit of $0.75 due to business disruptions arising from the cyber attack on the company's Change Healthcare unit in February, an increase of about $0.10 a share from the previous estimate, UnitedHealth ( UNH ) said in the Tuesday statement.

"We continue to work with customers to bring transaction volumes back to pre-event levels and to win new business with our now more modern, secure and capable offerings," Chief Financial Officer John Rex said in an earnings call with analysts, according to a Capital IQ transcript. "We expect to continue to build back the business to pre-attack levels over the course of 2025, and estimate next year's full year impact will be roughly half of the 2024 level."

For the three-month period ended Sept. 30, the health insurer reported adjusted EPS of $7.15, including $0.12 in business disruption impact but excluding $0.28 in direct response costs to the cyberattack. The latest result was higher than $6.56 reported in the prior-year quarter, and beat the Street's estimate of $7.03. Revenue climbed to $100.82 billion from $92.36 billion last year, topping analysts' $99.28 billion forecast.

The insurer's UnitedHealthcare segment, which provides health care benefits to people, including Medicare and Medicaid beneficiaries, generated revenue of $74.85 billion, up from $69.85 billion a year ago. Year-to-date, the number of people served domestically by the division grew by 2.4 million, the company said.

Revenue in the Optum business, which serves the global health care marketplace, advanced to $63.93 billion from $56.74 billion last year. Within the segment, Optum Health and Optum Rx logged revenue gains, while Optum Insight decreased to $4.93 billion from $4.98 billion last year.

Net margin declined to 6% from 6.3% in the 2023 quarter. UnitedHealth's ( UNH ) medical care ratio, which is used to measure medical costs as a percentage of premium revenue, rose to 85.2% from 82.3% last year. Total operating costs increased to $92.11 billion from $83.84 billion.

Price: 584.80, Change: -20.60, Percent Change: -3.40

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Huntington Ingalls' Q2 Earnings, Revenue Increase
Huntington Ingalls' Q2 Earnings, Revenue Increase
Aug 1, 2024
08:37 AM EDT, 08/01/2024 (MT Newswires) -- Huntington Ingalls Industries ( HII ) reported Q2 earnings Thursday of $4.38 per diluted share, up from $3.27 a year earlier. Analysts polled by Capital IQ expected $3.60. Sales and service revenue for the quarter ended June 30 was $2.98 billion, compared with $2.79 billion a year earlier. Analysts surveyed by Capital IQ...
--AbbVie Completes Acquisition of Cerevel Therapeutics
--AbbVie Completes Acquisition of Cerevel Therapeutics
Aug 1, 2024
08:37 AM EDT, 08/01/2024 (MT Newswires) -- Price: 185.30, Change: -0.02, Percent Change: -0.01 ...
Regeneron beats quarterly results on strong demand for eczema, eye treatments
Regeneron beats quarterly results on strong demand for eczema, eye treatments
Aug 1, 2024
Aug 1 (Reuters) - Drugmaker Regeneron Pharmaceuticals exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs. The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs. U.S. sales of...
Fox, Disney, Warner Bros Discovery's sports-streaming JV priced at $42.99/month
Fox, Disney, Warner Bros Discovery's sports-streaming JV priced at $42.99/month
Aug 1, 2024
(Reuters) -Venu Sports, the streaming service formed by Walt Disney, Fox and Warner Bros Discovery, will be priced at $42.99 per month with a seven-day free trial, it said on Thursday. The companies announced the service in February to woo younger viewers who are not tuned in to cable TV by bundling their broad portfolio of sports rights including the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved